Breast cancer highlights: Key findings from the San Antonio Breast Cancer Symposium: A U.S. perspective

Oncologist

Volumn 9, Issue 4, 2004, Pages 471-478

  Cristofanilli, Massimo ^a   Hortobágyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Dose dense chemotherapy; Endocrine therapy; Targeted therapies; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GEFITINIB; HORMONE RECEPTOR; MELPHALAN; METHOTREXATE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE; TAXANE DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN ANTIBODY;

ACNE; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLEEDING; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; HIGH RISK POPULATION; HUMAN; HYPERTENSION; NEUTROPENIA; PARTIAL MASTECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEINURIA; RASH; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; POSTMENOPAUSE; TEXAS;

EID: 3543008918     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-4-471     Document Type: Conference Paper

References (54)

1. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Cristofanilli M, Hortobagyi GN. Molecular targets in breast cancer: current status and future directions. Endocr Relat Cancer 2002;9:249-266.
3. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000:18;3758-3767.
4. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-2606.
5. ATAC Trialists' Group. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal women. Breast Cancer Res Treat 2001;69:210.
6. Baum M, Buzdar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first result of the ATAC randomised trial. Lancet 2002;359:2131-2139.
7. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive, breast cancer: status report 2002. J Clin Oncol 2002;20:3317-3327
8. ATAC Trialists' Group. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial in post-menopausal women with early breast cancer. Update efficacy results based on a median follow-up of 47 months. Breast Cancer Res Treat 2002;76(suppl):S32.
9. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
10. Allred DC, Bryant J, Land S et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP Protocol B-24. Breast Cancer Res Treat 2002;76(suppl):S36.
11. Fisher B, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000.
12. Fisher B, Ravdin RG, Ausman RK et al. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 1968;168:337-356.
13. Fisher B, Carbone P, Economou SG et al. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 1975;292:117-122.
14. Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-410.
15. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-942.
16. Eifel P, Axelson JA, Costa J et al. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001;93:979-989.
17. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
18. Nabholtz JM, Pienkowsky T, Mackey J et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002;21:36a.
19. Green MC, Buzdar AU, Smith T et al. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC-final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002;21:35a.
20. Norton L, Simon R. Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst 1977;58:1735-1741.
21. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977:61:1307-1317.
22. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-1047.
23. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-1206.
24. Citron M, Berry D, Cirrincione C et al. Superiority of dose-dense (D-D) over conventional scheduling (CS) and equivalence of sequential (SC) vs. combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALGB 9741, INT C9741). Breast Cancer Res Treat 2002;76(suppl 1):S32.
25. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
26. Arteaga CL, Winnier AR, Poirier MC et al. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 1994;54:3758-3765.
27. Robert N, Leyland-Jones B, Asmar L et al. Phase III comparative study of trastuzumab and paclitaxel with or without carboplatin in patients with Her-2/neu positive advanced cancer. Breast Cancer Res Treat 2002;76(suppl):S37.
28. Albain K, Elledge R, Gradishar WJ et al. Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 2002;76(suppl 1):S33.
29. Miller KD, Rugo HS, Cobleigh MA et al. Phase III trial of capecitabine (Xeloda®) plus bevacizumab (Avastin™) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 2002;76(suppl 1):S37.
30. Chan KC, Knox WF, Gee JM et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res 2002;62:122-128.
31. Wakeling AE, Guy SP, Woodburn JR et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-5754.
32. Pivot X, Asmar L, Hortobagyi GN. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer. Int J Oncol 1999;15:381-386.
33. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001;92:1759-1768.
34. Zelek L, Barthier S, Riofrio M et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001;92:2267-2272.
35. Kramer JA, Curran D, Piccart M et al. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 2000;36:1498-1506.
36. Pritchard KI. Liver metastases: can our understanding of their biology and prognostic value contribute to a strategy for optimum therapeutic management? Eur J Cancer 1997;33(suppl 7):S11-S14.
37. van der Pluijm G, Sijmons B, Vloedgraven H et al. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res 2001;16:1077-1091.
38. Ravindranath N, Wion D, Brachet P et al. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 2001;22:432-443.
39. Marquez DC, Lee J, Lin T et al. Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine 2001;16:73-81.
40. Strawn LM, McMahon G, App H et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996;56:3540-3545.
41. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
42. Shawver LK, Lipson KE, Fong TAT et al. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discovery Today 1997;2:50-63.
43. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995;13:765-782.
44. Linderholm B, Tavelin B, Grankvist K et al. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 1998;16:3121-3128.
45. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-850.
46. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001;19:851-856.
47. Galmarini FC, Galmarini CM, Sarchi MI et al. Heterogeneous distribution of tumor blood supply affects the response to chemotherapy in patients with head and neck cancer. Microcirculation 2000;7:405-410.
48. Denekamp J, Dasu A, Waites A. Vasculature and microenviromental gradients: The missing links in novel approaches to cancer therapy? Adv Enzyme Regul 1998:38:281-299.
49. Vajkoczy P, Menger MD, Vollmar B et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intracavital multi-fluorescence videomicroscopy. Neoplasia 1999;1:31-41.
50. Bhujwalla ZM, Artemov D, Natarajan K et al. Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 2003;9:355-362.
51. Sweeney CJ, Miller KD, Sissons SE et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-3372.
52. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.
53. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
54. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.